AHA SCIENTIFIC STATEMENT

USE OF MARIJUANA: EFFECT ON BRAIN HEALTH

A SCIENTIFIC STATEMENT FROM THE AMERICAN HEART ASSOCIATION

©2022 American Heart Association, Inc. All rights reserved.
THE AMERICAN ACADEMY OF NEUROLOGY AFFIRMS THE VALUE OF THIS STATEMENT AS AN EDUCATIONAL TOOL FOR NEUROLOGISTS

American Heart Association
WRITING GROUP MEMBERS:
FERNANDO D. TESTAI, MD, PHD;
PHILIP B. GORELICK MD, MPH;
HUGO J. APARICIO, MD, MPH;
FRANCESCA M. FILBEY, PHD;
RAUL GONZALEZ, PHD;
REBECCA F. GOTTESMAN, MD, PHD;
MIRIAM MELIS, PHD;
MARIANN R. PIANO, RN, PHD;
TIZIANA RUBINO, PHD;
SARAH SONG, MD;

ON BEHALF OF THE AMERICAN HEART ASSOCIATION BRAIN HEALTH SCIENCE SUBCOMMITTEE OF THE STROKE COUNCIL; COUNCIL ON ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY; COUNCIL ON CARDIOVASCULAR AND STROKE NURSING; COUNCIL ON LIFESTYLE AND CARDIOMETABOLIC HEALTH; AND COUNCIL ON PERIPHERAL VASCULAR DISEASE.
ABSTRACT
ABSTRACT

- Marijuana is perceived as a harmless drug and its recreational use has gained popularity among young individuals.
- The concentration of active ingredients in recreational formulations has gradually increased over time.
- High-potency illicit cannabinomimetics are now available and the consumption of cannabis in the general population is rising.
- Data from preclinical models demonstrate that cannabinoid receptors are expressed in high density in areas involved in cognition and behavior, particularly during periods of active neurodevelopment and maturation.
- In addition, growing evidence highlights the role of endogenous cannabinoid pathways in the regulation of neurotransmitter release, synaptic plasticity, and neurodevelopment.
- In animal models, exogenous cannabinoids disrupt these important processes and lead to cognitive and behavioral abnormalities.
- These data correlate with the higher risk of cognitive impairment reported in some observational studies done in humans.
- It is unclear whether the effect of cannabis on cognition reverts after abstinence.
- However, this evidence along with the increased risk of stroke reported in marijuana users raise concerns about its potential long-term effects on cognitive function.
- This statement reviews:
  - The safety of cannabis use from the perspective of brain health,
  - Describes mechanistically how cannabis may cause cognitive dysfunction,
  - Advocates for a more informed healthcare worker and consumer about the potential for cannabis to adversely affect the brain.
INTRODUCTION
INTRODUCTION

• Marijuana, or cannabis, was considered an illicit drug for decades.

• However, in many parts of the world, cannabis has been legalized for medical use or decriminalized for recreational or medicinal applications.

• This shift in attitude has resulted in a rapid increase in its use.

• It has been estimated that approximately 183 million people in the world used marijuana in 2014\(^1\) and 22 million met criteria for cannabis use disorder in 2016.

• According to the 2002-2019 National Survey on Drug Use and Health, the proportion of US Americans aged >12 that used marijuana in the last year increased gradually from 11% in 2002 to 18% in 2019.

• The use of marijuana has gained popularity particularly among adolescents and young adults with approximately 36% of 12\(^{th}\) graders and 43% of college students reporting having used it in the last year.

• There is evidence suggesting that the potency of cannabis products in the United States, measured by the concentration of the primary psychoactive constituent of marijuana, \(\Delta^9\)-tetrahydrocannabinol (THC), has gradually increased from approximately 4% in 1995 to 15% in 2018.

• Cannabinoid receptors are expressed in high density in areas of the brain involved in executive function and memory, such as the hippocampus, amygdala and prefrontal cortex (PFC), particularly during periods of active brain development.
INTRODUCTION

• Cannabinoids may acutely impair memory and behavioral inhibition.
• They also regulate anxiety and can produce psychosis-like effects.
• Significantly, there is evidence showing that age of exposure may influence the effect of cannabinoids on cognitive function, for example, the prenatal, perinatal and adolescent periods may be particularly sensitive to these compounds.
• Data obtained in preclinical models have shown that cannabis and its associated signaling pathways regulate neurotransmission and play an active role in key cerebral processes, including neuroinflammation, neurogenesis, neural migration, synaptic pruning, and white matter development.
• Experimental data shows that cannabinoids can regulate the functioning of different cytochrome-P450 isoforms and uridine 5’-diphospho--glucuronosyltransferases.
• Thus, there is a potential risk for drug-to-drug interactions with medications commonly used by the elderly, such as warfarin, anti-arrhythmic agents, sedatives, and anticonvulsants
• These factors have raised concerns about the potential effect of cannabis on cognitive vitality.
• The goal of this statement is to critically appraise the safety of cannabis use from the perspective of brain health.
CANNABIS AND ENDOCANNABINOIDS
CANNABIS AND ENDOCANNABINOIDS

• Anandamide and 2-arachidonoyl-glycerol are endogenous bioactive lipids that activate two G-protein-coupled receptors designated as cannabinoid receptor type 1 (CB1) and 2 (CB2).

• These lipids, called endocannabinoids, are not stored in vesicles but synthesized on demand.

• The system formed by the cannabinoid receptors CB1 and CB2, endogenous ligands, and enzymes involved in their production and degradation is known as the endocannabinoid system (ECS). The detailed description of the composition and regulation of the ECS is beyond the scope of this publication and has been extensively reviewed elsewhere.

• Phytocannabinoids are exogenous cannabinoids extracted from flowering plants from the cannabis genus, including Cannabis sativa, Cannabis indica and Cannabis ruderalis.

• Whether these are species or subspecies is a matter of debate.

• More than 100 phytocannabinoids have been extracted from these plants, with THC and cannabidiol (CBD) being the most abundant.

• The relative concentration of THC and CBD in these strains is variable.

• In general, cannabis cultivars can be classified based on the cannabinoid produced as chemotype I (THC-rich), II (THC/CBD-balanced) III (CBD-rich), IV (cannabigerol-rich) or V (cannabinoid-free).

• Tetrahydrocannabinol is a psychoactive alkaloid that signals through CB1 and CB2 receptors.

• Cannabinoid receptor type 1 is abundantly expressed in peripheral and central neural cells.
CANNABIS AND ENDOCANNABINOIDS

• In the periphery, CB1 localizes to sympathetic nerve terminals and sensory neurons.
• In the central nervous system, it is mainly expressed in presynaptic membranes of excitatory and inhibitory neurons where it regulates the vesicular release of dopamine, gamma aminobutyric acid (GABA) and glutamate.
• In comparison, CB2 is mainly expressed in immune cells, including microglia.
• Cannabidiol is a nonpsychoactive cannabinoid that has antioxidant and anti-inflammatory properties.
• It is thought that CBD exerts some of the beneficial effects that phytocannabinoids have in Dravet syndrome and Lennox–Gastaut syndrome.
• Furthermore, studies done in preclinical models suggest that CBD is beneficial in Alzheimer’s disease, cerebral ischemia, multiple sclerosis and other neurologic disorders.
• The therapeutic potential of CBD is being investigated in different clinical trials.
• In comparison to THC, CBD signals through different pathways but does not activate CB1 and CB2.
At low concentration, CBD blocks the orphan G-protein-coupled receptor-55, the equilibrative nucleoside transporter 1, and the transient receptor potential of melastatin type 8 (TRPM8) channel.

It also activates the 5-HT1 receptor, the transient receptor potential of ankyrin type 1 channel, and α3 and α1 glycine receptors.

At high concentration, CBD activates the nuclear peroxisome proliferator-activated receptor γ and the transient receptor potential of vanilloid type 1 and 2.

Several cannabinoids have received approval in different countries for the treatment of specific medical conditions.

In addition, high-potency synthetic cannabimimetics, such as Spice, are available in the illegal market (Table 1).
<table>
<thead>
<tr>
<th>Cannabinoid Type</th>
<th>Active Ingredient</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medical</strong>&lt;sup&gt;15,16,16&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cesamet</strong>&lt;sup&gt;¶&lt;/sup&gt;</td>
<td>Nabilone (synthetic THC analog)</td>
<td>• Treatment of refractory cancer chemotherapy-associated nausea and vomiting&lt;sup&gt;¶&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Marinol (pill)</strong>&lt;sup&gt;¶&lt;/sup&gt;</td>
<td>Dronabinol (synthetic THC)</td>
<td>• Anorexia with weight loss in patients with acquired immune deficiency syndrome or cancer&lt;sup&gt;¶&lt;/sup&gt; • Treatment of refractory cancer chemotherapy-associated nausea and vomiting&lt;sup&gt;¶&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Syndros (solution)</strong>&lt;sup&gt;¶&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Epidiolex</strong>&lt;sup&gt;¶&lt;/sup&gt;</td>
<td>Purified CBD</td>
<td>• Seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome in patients older than 1 year&lt;sup&gt;¶&lt;/sup&gt; • Seizures associated with tuberous sclerosis complex in patients older than 1 year&lt;sup&gt;¶&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Sativex</strong>&lt;sup&gt;¶&lt;/sup&gt;</td>
<td>Nabiximols (extract of THC, CBD and other minor cannabinoids, terpenoids, and flavonoids)</td>
<td>• Adjunctive therapy for symptomatic treatment of refractory spasticity in adult multiple sclerosis patients Indication&lt;sup&gt;¶&lt;/sup&gt; • Adjunctive treatment for symptomatic neuropathic adult patients in patients with multiple sclerosis Indication&lt;sup&gt;¶&lt;/sup&gt; • Adjunctive treatment for patients with advanced cancer with refractory severe pain Indication&lt;sup&gt;¶&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Illicit</strong>&lt;sup&gt;¶&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>K2, Spice, Kronic, Kaos</strong>&lt;sup&gt;¶&lt;/sup&gt;</td>
<td></td>
<td>• Originally synthesized to study the endocannabinoid system • Bind cannabinoid receptors with high affinity • Hallucinations, agitation, psychosis, short-term memory loss, seizures, coagulopathy and myocardial infarct have been associated with the use of these products</td>
</tr>
</tbody>
</table>

*Approved by the Food and Drug Administration
Approved by the Health Products and Food Branch of Health Canada

CBD: cannabidiol; TCH: Δ⁹-tetrahydrocannabinol
NEUROBIOLOGICAL ACTIONS OF CANNABIS IN ANIMAL MODELS
NEUROBIOLOGICAL ACTIONS OF CANNABIS IN ANIMAL MODELS

- Molecular and cellular mechanisms underlying the effects of cannabis on the developing brain are mainly inferred from preclinical studies which permit controlling for social and environmental factors that could influence outcomes of interest.

- Animal models allow the investigation of a range of human age-related behavioral factors (e.g., novelty and sensation seeking, impulsivity, risk-taking behaviors) and key stages of neurodevelopment that are conserved across many mammalian species.

- However, many individual (e.g., species, strain, age) and experimental (e.g., design, drug, dose, delivery, regimen) variables along with objective endpoints (e.g., behavioral paradigm, experimental technique) have contributed to equivocal findings across studies.

- Nonetheless, experimental animal models of prenatal and adolescent cannabis exposure have proven fundamental in disclosing the underlying neurobiological mechanisms that might explain several clinical neuropsychiatric outcomes outlined below.

- Animal models have been used to examine the role of the ECS in the modulation of synaptic plasticity, a process that allows the brain to change and adapt to new information.

- The ECS modulates synaptic plasticity by affecting the strength of interneuronal connections and, ultimately, the functioning of neuronal networks.

- From the mechanistic standpoint, THC activates cannabinoid receptors in the brain, thus interfering with physiological actions of endocannabinoids.
NEUROBIOLOGICAL ACTIONS OF CANNABIS IN ANIMAL MODELS

• Spatial and time resolution of endocannabinoid production is pivotal for correct processing of different brain functions such as higher-order cognition, memory, reward, mood and stress sensitivity.

• Consequently, THC, activating nonspecifically CB1 receptors in the brain, disrupts the fine-tuning of synaptic activity exerted by endocannabinoids, eventually impairing connectivity of neuronal networks and brain functionality.

• Although incompletely understood, the way in which THC disrupts memory and learning may be through its differential effect on neurotransmitter release and binding to CB1 receptors.

• For example, THC activates CB1 receptors located on GABAergic interneurons, which represent nearly ¾ of the brain CB1 receptors, and astrocytes resulting in the release of hippocampal glutamate.

• Concomitantly, THC affects the transmission of other neurotransmitters involved in the modulation of memory, such as acetylcholine, adenosine and serotonin.
NEUROBIOLOGICAL ACTIONS OF CANNABIS IN ANIMAL MODELS

- Furthermore, THC activation of CB1 receptors present on mitochondria leads to decreased cellular respiration and ATP (adenosine triphosphate) supply.
- ATP is fundamental in maintaining and regulating neurotransmission and its reduction might contribute to THC-induced cognitive deficits.
- Repeated exposure to cannabis, especially during the adolescent developmental period, may be especially harmful to brain health and cause structural, molecular and functional alterations of brain circuits, particularly in the PFC and hippocampus.
- Chronic THC exposure induces CB1 receptor downregulation and desensitization that appear more intense and widespread after adolescent exposure as opposed to adulthood exposure.\(^2\)
- Data obtained in experimental models showed that these effects could have implications for neurodevelopmental processes in which the ECS plays a role.
- Accordingly, chronic THC exposure during adolescence may disrupt dynamic changes occurring in glutamatergic and GABAergic systems, leading to excessive synaptic pruning (i.e. loss of synaptic contacts), long-term dysfunction in prefrontal excitatory/inhibitory balance, and desynchronization of PFC neuronal networks, which also dysregulate the mesolimbic dopaminergic pathway (Figure 1).
The effect of Δ⁹-tetrahydrocannabinol (THC) on different neurobiological processes constitutes a continuum throughout the lifetime of an individual. However, two windows of brain vulnerability have been identified in preclinical models. Colored boxes represent the different processes that have been demonstrated to be affected upon exposure to THC during these sensitive developmental periods.
NEUROBIOLOGICAL ACTIONS OF CANNABIS IN ANIMAL MODELS

• These changes may represent the molecular underpinnings of cognitive deficits and altered emotional reactivity and social behavior observed long after adolescent chronic THC exposure.

• Long-term changes in brain functionality induced by THC exposure during adolescence might also arise from epigenetic modifications with a marked reprogramming of the transcriptome, mainly affecting genes related to synaptic plasticity processes.

• Remarkably, these effects have not been reported after adult THC exposure.

• In addition to the effects on neuron cellular and subcellular components, recent evidence suggests alterations in glial cells as having a key role in the actions of THC.

• Chronic THC exposure activates microglia and/or astrocytes to produce inflammatory cytokines.

• The chronic administration of THC during adolescence increased the microglial expression of the proinflammatory mediators TNF-α, iNOS, and COX-2 by 60%, 130% and 80%, respectively, and reduced the expression of the anti-inflammatory cytokine IL-10 by 30% in the PFC.

• Remarkably, the resulting neuroinflammatory response was associated with memory impairment during adulthood.

• Dose constitutes an additional important variable to consider. Most studies describe detrimental effects of THC in models of heavy cannabis use in middle adolescence.

• However, even lower doses may produce these same effects when administered earlier in adolescence.
EFFECT OF PRENATAL EXPOSURE TO CANNABINOID AGONISTS
A recent study examined associations between prenatal cannabis exposure and various indicators of mental and neurocognitive health in a sample of 11,489 youth.

Self-report of maternal cannabis use during pregnancy was associated with various adverse outcomes among youth at ages 9 to 10, including poorer performance on scores of neurocognitive functioning and total intracranial volumes, even after controlling for potential confounders.

Several reviews describe prenatal cannabis exposure (PCE) sequelae in preclinical models, but we will focus on mechanistic insights inferred from animal studies recapitulating the neuropsychiatric features of clinical outcomes.

The detrimental effect of PCE on cognitive processing and emotional regulation of the progeny has been ascribed to changes in intrinsic and synaptic properties and plasticity of cortical (e.g., PFC), limbic (e.g., amygdala, hippocampus) and midbrain (e.g., ventral tegmentum) regions.

Changes in the balance of excitatory and inhibitory input strength along with alterations in how principal and inter-neurons receive, integrate and convey information have been observed in these neuroanatomical areas.

Aberrant glutamatergic function is a common hallmark as indexed by changes in the expression and function of ionotopic and metabotropic receptors, and in dynamic regulation of glutamate levels by glutamate transporters at both synaptic cleft and extra-synaptic spaces.
EFFECT OF PRENATAL EXPOSURE TO CANNABINOID AGONISTS

• These changes largely depend on the alterations of endocannabinoid signaling pathways caused by exogenous cannabinoids during development and throughout ontogenesis (e.g., neural proliferation, survival, directional axonal growth).

• Defects in ECS function may also account for the interneuronopathy observed in many brain regions of PCE offspring, a phenomenon often more prominent in females than in males.

• Remarkably, in the PFC, this persistent inhibitory circuit deficit is also associated with a delayed switch of GABA from its excitatory role early on in development to a classic inhibitory function exerted throughout the CNS later in life.

• This is particularly relevant as the GABA switch represents a critical milestone during neurodevelopment.

• Any alteration in the normal and predictable temporal sequence of these periods, such as delays, stalls or accelerations, imposed by PCE may lead to perturbations of offspring cognitive processing and emotional behavior.

• It was observed that marijuana use leads to dysregulation of monoaminergic pathways and stress response systems.

• Prenatal cannabis exposure hampers the maturation of monoamines, which also exert trophic actions on target neurons and afferent terminals.

• This phenomenon may depend on epigenetic modifications and may be implicated in aberrant reward signaling.
EFFECT OF PRENATAL EXPOSURE TO CANNABINOID AGONISTS

• PCE is associated with an endophenotype in the offspring, which displays protracted dysregulation of stress responsivity that is not explained by glucocorticoid levels.

• Remarkably, a susceptibility to acute and chronic stress is tied to many psychiatric disorders, ranging from depressed mood and psychoses to substance use disorders and anxiety.

• A deeper understanding of how PCE interferes with endocannabinoid signaling during neurodevelopment would allow us to explore potential interventions aimed at restoring or reprogramming the hierarchical progression of developmental milestones.
EFFECTS OF MARIJUANA USE ON HUMAN COGNITION
EFFECTS OF MARIJUANA USE ON HUMAN COGNITION

• Acute use of marijuana is associated with impairment of working and episodic memory, behavioral disinhibition, and impulsivity which can affect performance in real-world activities.

• A meta-analysis from 2016 showed that the odds of being involved in a motor vehicle accident was increased 36% in cannabis users relative to non-users.

• A crossover clinical trial published in 2020 investigated the effect of different cannabis products in relation to on-road driving tests.

• The standard deviation of lateral position, a measure of lane weaving, swerving, and overcorrection, was 20.29 cm at 40-100 min following inhalation of THC-dominant cannabis and 21.09 cm after inhalation of a mixture of THC and CBD.

• Interestingly, the standard deviation of lateral position after inhalation of CBD-dominant cannabis was similar to that in the placebo group (18.21 cm vs. 18.26 cm)33. These observations illustrate the differential short-term effect of THC and CBD on cognition.

• There is also evidence suggesting that the acute effects of cannabinoids are transient and can be influenced by the development of tolerance and use of other drugs.

• The long-term effect of cannabis on cognition, however, is less well established.
EFFECTS OF MARIJUANA USE ON HUMAN COGNITION

• Recent meta-analyses report residual effects of cannabis use on neurocognition, consistent with prior research.

• A meta-analysis by Lovell et al in 2020 focused on adult near-daily cannabis use for more than two years and found global neurocognition among users (n=849) to be about a quarter of standard deviation worse than non-cannabis users (n=764).

• Four of the seven domains investigated (decision-making, verbal learning, retention, executive function) showed significant effect sizes ranging from Hedges’ g = -0.52 to -0.18.

• A meta-analysis of cannabis users aged <26 (n=2,152) and non-cannabis users (n=6,575) also showed a quarter of standard deviation difference in global neurocognitive performance, but with more specific domains affected36, albeit with smaller effect size compared to Lovell et al (2020).

• Both lacked support for worse neurocognition in early adolescence, as neither found that age of onset of cannabis use influenced the association between exposure and cognitive performance.
EFFECTS OF MARIJUANA USE ON HUMAN COGNITION

• In contrast to these meta-analyses, large longitudinal studies provide stronger causal inferences by examining change over time.

• In the Coronary Artery Risk Development in Young Adults (CARDIA) study, 3,385 participants aged 18 to 30 years were followed longitudinally.

• Marijuana use was assessed periodically in the 25-year follow up. Cognitive assessment was completed 25 years after inception.

• In this study, cumulative years of exposure to marijuana was associated with worse verbal memory (0.13 lower standard deviations in the verbal memory test for each additional 5 years of exposure to marijuana)\(^3\).\(^7\).

• Longitudinal, co-twin studies employ a research design that additionally controls for shared variance from genetic and environmental factors.

• Two large longitudinal twin studies (n=3,066) with neurocognitive measures collected before (ages 9 to 12) and after cannabis exposure (ages 17-20) reported that declines in vocabulary and general knowledge were associated with being a cannabis user, but not with amount of cannabis consumed.

• Twins discordant for cannabis use showed no differences in IQ declines.

• Thus, differences were likely due to shared risk factors.
EFFECTS OF MARIJUANA USE ON HUMAN COGNITION

• Using a similar design, Meier et al. reported that lower IQ predated cannabis use with no evidence of actual IQ declines among 1989 twins assessed at ages 5, 12, and 18.

• Ross et al. evaluated other aspects of neurocognition among 856 individual twins and reported only one within-family effect out of 70 that were tested.

• Specifically, frequency of cannabis use at age 17 was associated with poorer executive functioning at age 23, but executive functioning problems predating cannabis use could not be ruled out.

• Magnetic resonance imaging (MRI) techniques demonstrate differential associations of cannabis use with brain structure and function.

• In terms of brain structure, alterations related to cannabis use have been mixed.

• In a longitudinal study including 1,598 MR images done in adolescents at baseline and 5-year follow up, a dose-dependent association was observed between cannabis use and PFC thinning.

• On the other hand, while a meta-analysis found that regular cannabis consumption was associated with smaller hippocampal (standardized mean difference [SMD] 0.14, 95% CI 0.02-0.27), medial orbitofrontal cortex (SMD 0.30, 95% CI 0.15-0.45) and lateral orbitofrontal cortex (SMD 0.19, 95% CI 0.07-0.32) volumes relative to non-cannabis users, brain volumes were not associated with cannabis use duration and dosage.
EFFECTS OF MARIJUANA USE ON HUMAN COGNITION

• Other large studies have reported null effects.
• In two large twin samples from the United States (n=474) and Australia (n=622), cannabis use was unrelated to volumes of the thalamus, caudate nucleus, putamen, pallidum, hippocampus, amygdala and nucleus accumbens.
• A multi-site study of cortical surface measures (n=262) reported no difference in cortical thickness, surface area, and gyrification index in (i) cannabis users vs. non-users, (ii) cannabis dependence vs. non-dependence vs. non-users, and (iii) early adolescent vs. late adolescent onset of cannabis use vs. non-users.
• Thus, brain structural abnormalities related to cannabis use are inconsistent.
• Functional MRI (fMRI) studies report more robust effects, particularly after prolonged cannabis use.
EFFECTS OF MARIJUANA USE ON HUMAN COGNITION

• A meta-analysis of task-based fMRI studies in current adult and adolescent users found abnormalities in activation in both age groups.

• Relative to non-using controls, adult cannabis users had greater brain activation in the superior (seed-based d mapping [SDM-Z] = 1.561; p<0.002) and posterior transverse temporal (SDM-Z = 1.479; p<0.003) and inferior frontal gyri (SDM-Z = 1.568; p<0.002) and less activation in the striatum (SDM-Z = -1.843; p<0.001), insula (SDM-Z = -1.637; p<0.001) and middle frontal gyrus across different tasks.

• Adolescent cannabis users also had greater activation in the inferior parietal gyrus (SDM-Z = 1.06; p<0.001) and putamen (seed-based d mapping = 1.008; p<0.001) compared to non-users across various tasks, suggesting compensatory neuroadaptive mechanisms.

• These functional abnormalities persist despite cessation of cannabis use and beyond the period when THC metabolites are detectable.
EFFECTS OF MARIJUANA USE ON HUMAN COGNITION

• A meta-analysis of the same adolescent studies found that >25-day abstinent adolescent cannabis users also exhibited greater activation in the right inferior frontal gyrus in addition to other areas relevant for executive functioning and self-regulatory mechanisms.

• Several recent studies examined cannabis effects in vulnerable populations and those using medical marijuana.

• A meta-analysis focused only on cannabis users with psychosis aged <25 years (n=529) and non-cannabis using controls with psychosis (n=901).

• In this study, there were significant differences in three of 11 domains assessed (premorbid IQ, Hedges’ g = 0.40 [standardized effect size]; current IQ, Hedges’ g = -0.17; working memory, Hedges’ g = -0.76).

• Among a sample of 215 adult chronic pain patients provided daily herbal cannabis containing 12.5% THC for 1 year, no significant neurocognitive differences were found compared to 216 controls.

• This is in line with a study of patients with multiple sclerosis in response to oral dronabinol that found no significant differences in MRI-derived measures, including annual percentage of brain volume change and occurrence of new lesions, following 12 months of use.

• These clinical trials suggest no significant adverse effect of THC on neurocognitive symptoms in specific clinical populations.
EFFECTS OF MARIJUANA USE ON CEREBROVASCULAR RISK AND DISEASE
CEREBROVASCULAR RISK FACTORS

• Similar to the literature linking marijuana use with cardiovascular outcomes, evidence that marijuana consumption increases the prevalence of specific cerebrovascular risk factors and disease is limited by a preponderance of observational studies, cross-sectional studies, case reports and case series prone to potential publication and other biases.

• Postulated adverse effects of marijuana use may include: sympathetic nervous system activation, blood pressure changes, platelet activation, and electrophysiological effects.

• Concomitant tobacco smoking and other substance use and abuse possibly contribute to these effects, which may be short-term and have been mostly studied in low-risk populations, such as younger adults.

• These factors may explain why many longitudinal studies linking marijuana use and cardiovascular or metabolic risk factors have been negative after multivariable adjustment for unhealthy behaviors such as diet and tobacco smoking.

• Hypertension, in particular, is an important risk factor for ischemic stroke, hemorrhagic stroke, and subarachnoid hemorrhage.

• With marijuana use, the most common acute reaction in humans is a decrease in blood pressure, due to cannabinoid effects on the vasculature and autonomic nervous system.

• Despite this physiologic reaction, limited studies using the National Health and Nutrition Examination Survey showed a modest association of recent cannabis use with higher systolic blood pressure and higher prevalence of hypertension among current users aged 30–59 years.
CEREBROVASCULAR RISK FACTORS

- Heavy users, defined as use of marijuana or hashish in >20 out of the past 30 days, had higher odds of abnormal blood pressure compared to never users.

- Although this difference remained statistically significant after adjustment for age, sex, race, ethnicity, body mass index, education, and survey year, it was no longer statistically significant after additional adjustment for current tobacco and binge alcohol use (aOR 1.47, 95% CI 0.99–2.16).

- The relationship between marijuana use and elevated blood pressure, especially among heavy users, may drive longer-term associations with cerebrovascular outcomes, though this mechanism remains to be studied.

- Prior cardiovascular disease, such as myocardial infarction (MI) or atrial fibrillation (AF), is also an important risk factor for stroke.

- Case reports of MI after marijuana use are mainly among young adults who lack vascular risk factors, with onset of MI shortly after use.

- Risk of MI was elevated 4.8-fold within an hour after smoking marijuana, compared with periods of nonuse.

- This association demonstrates the potential role of marijuana as an acute trigger for cardiovascular disease.
CEREBROVASCULAR RISK FACTORS

• Over 25 years of follow up, among 5,113 adult participants in the Coronary Artery Risk Development in Young Adults study, cumulative or recent marijuana use was not associated with coronary heart disease, stroke, or cardiovascular disease mortality.

• This contrasts with a population-based, multi-institutional database study that observed an increased risk of 3-year cumulative incidence of MI among marijuana users compared to controls (1.37% vs 0.54%; RR 2.54, 95% CI 2.45-2.61).

• Similarly, marijuana use appears to be a trigger for AF.

• Data from the Nationwide Inpatient Sample (NIS) show that the percentage of individuals with cannabis use disorder discharged in the post-legalization period (2010 to 2014) with the diagnosis of arrhythmia increased 31%.

• However, in a study of patients hospitalized for heart failure, marijuana users had a reduced odds of AF, compared to nonusers (aOR 0.87, 95% CI 0.77-0.98).

• Simultaneous use of cocaine, stimulants, and other drugs may be responsible for observations of AF among marijuana users, though this remains to be fully studied outside of observational and cross-sectional reports.

©2022 American Heart Association, Inc. All rights reserved.
RISK OF STROKE AND TRANSIENT ISCHEMIC ATTACK

• Several case reports and case series mostly in young individuals suggest a relationship between recent and heavy cannabis use and risk of stroke.

• In contrast, findings among case-control, population-based studies, as well as those conducted using outpatient or inpatient national databases or hospital electronic health records have been equivocal, depending on the study design, covariates considered in the analysis, and source of the population being studied.

• Inconsistent associations can also be attributable to the presence of comparison groups, and whether adjustment of other important risk factors were considered, along with attention to potential confounding by other risk factor and lifestyle features between cannabis users and nonusers.

• In one case-control study using cannabis urine screens to identify cannabis users, the authors found an association between cannabis use and the risk of ischemic stroke and TIA, but the association was not significant when tobacco use was included as a covariate (aOR 1.59; 95% CI 0.71–3.70) among subjects aged 18–55 years with and without stroke.

• Similarly, after adjusting for cigarette smoking and alcohol use, another study found no association between cannabis use in young adulthood and the occurrence of fatal and nonfatal stroke later in life among Swedish men, in up to 38 years of follow-up.

• Data from studies which have examined more specifically the dose or amount of cannabis consumed within a designated timeframe suggest regular cannabis use may increase the risk of stroke.
RISK OF STROKE AND TRANSIENT ISCHEMIC ATTACK

- Using data from population-based surveys, investigators have reported that when comparing no cannabis use versus heavy cannabis use in the past year, cannabis use was associated with an increased risk for the occurrence of nonfatal stroke and TIA.

- Another study found that recent (within the last 30 days) and frequent (>10 days/month) cannabis use was associated with increased risk for the occurrence of stroke compared to nonusers, whereas less frequent cannabis use (≤10 days/month or less than weekly in the past year) was not associated with increased risk.

- Using several ICD-9-CM codes for marijuana use, an NIS study found that cannabis use among men and women hospitalized between 2004 and 2011 was associated with a 17% increased relative risk for acute ischemic stroke in a multivariable-adjusted analysis.

- Concomitant use of tobacco with cannabis increased the risk to 31%.

- Similarly, a separate study using the NIS, but between 2009 and 2010, observed a higher odds of stroke among cannabis users (OR 1.24, 95% CI 1.14-1.34).

- In contrast, investigators using electronic health record data from patients admitted to a single center between 2015-2017 found that testing positive for cannabis use was not associated with the risk of ischemic stroke, compared to patients testing negative, even after adjusting for numerous confounders, including age, cigarette smoking and comorbidities.

- There may be certain populations or scenarios where cannabis use can be meaningfully linked to stroke.
RISK OF STROKE AND TRANSIENT ISCHEMIC ATTACK

• A study of a large longitudinal cohort of Canadian pregnant women including >1 million participants between 1989 and 2019 with follow-up at 30-year observed that cannabis use disorder was associated with a doubling of risk for hemorrhagic stroke (HR 2.08, 95% CI 1.07–4.05), but no increased risk for ischemic or other cerebrovascular disease.

• Because of the theoretical vasoactive effect of cannabis, its use has been implicated in some cases of reversible cerebral vasoconstriction syndrome (RCVS), with 6 of 24 non-idiopathic RCVS cases at one Colorado stroke center attributed to marijuana use.

• An elevated risk of stroke from intracranial arterial stenosis has been described among young cannabis users aged 18-45, wherein vasospasm or RCVS may be potential mechanisms.

• Studies done in experimental models have shown that cannabinoids exert complex effects on cardiac contractility, vascular tone, and atherogenesis.

• Both vasodilatation and vasoconstriction responses were observed, depending on the experimental model and cannabinoid utilized.

• CB1 activation promotes inflammation, upregulates the production of reactive oxygen species and activates pro-apoptotic pathways in endothelial cells and cardiomyocytes.
RISK OF STROKE AND TRANSIENT ISCHEMIC ATTACK

• In addition, it induces endothelial dysfunction and vascular smooth muscle cell proliferation and migration.
• These processes have been linked to cardiac dysfunction and the development of atherosclerosis.
• This is in contrast to the atheroprotective role associated with CB2.
• Acute cardiovascular events and stroke have also been reported in patients using synthetic cannabinoids.
• Spice is associated with idiopathic thrombocytopenic purpura which increases the risk of major hemorrhage.
• In addition, intracranial hemorrhage in Spice users has been linked to the presence of bradifacoum, an adulterant considered a superwarfarin.
EDUCATION AND FUTURE DIRECTIONS
EDUCATION AND FUTURE DIRECTIONS

• Our understanding of the ramifications of cannabis consumption on brain health is limited but rapidly evolving.

• Observational studies have produced conflicting results in relation to the effect of marijuana on different outcomes of interest, including hypertension, AF, MI and cognition.

• Several methodologic factors may explain these apparent contradictions.

• First, given its historical classification as an illicit drug, the use of marijuana has been underreported for generations.

• The inclusion of marijuana users in the control group of observational studies that rely on self-reported use could underestimate its effect on brain health.

• Second, several behaviors, such as smoking and alcohol use, are associated with marijuana consumption and can influence stroke risk and brain connectivity.

• Information often missing is on frequency of exposure to these factors limits our ability to determine with accuracy the independent effect of marijuana.

• Third, the time of exposure, frequency of use, and bioavailability of marijuana, which is affected by the route of administration, diet, and concomitant use of medications that may affect its metabolism, are reported inconsistently.

• Fourth, THC and CBD have different pharmacologic effects.
EDUCATION AND FUTURE DIRECTIONS

• While the use of THC has been associated with detrimental effects, CBD appears to have therapeutic potential in some neurologic disorders.

• The absolute and relative concentrations of these compounds differ based on the strain of cannabis plant and methodology used for the extraction of the active ingredients.

• Fifth, the gradual increase in the potency of marijuana used recreationally limits the relevance of older studies.

• Sixth, different factors impede the development of long-term placebo-controlled studies, including ethical reasons and the psychotropic effect of THC which cannot be blinded.
EDUCATION AND FUTURE DIRECTIONS

• Social media may emphasize a beneficial role for marijuana and the general population may perceive it as a harmless drug.

• However, the emerging evidence linking marijuana use to cardiovascular events and stroke as well as the potential and demonstrated drug-to-drug interactions between marijuana and medications commonly used in the general population call for caution and highlight the potential importance of active surveillance programs.

• Additionally, the high density of cannabinoid receptors in areas involved in executive function and memory, the dose-dependent detrimental effect of THC on working and episodic memory, and the role of cannabinoid-associated biochemical pathways on synaptic plasticity and neuronal development raise concern that chronic exposure to marijuana may affect brain health.

• There is lack of agreement on whether the effects of marijuana completely resolve after months of abstinence.

• However, the disruption of endocannabinoid signaling pathways during the prenatal and perinatal periods and in adolescence may be detrimental to neurodevelopment.

• Key points discussed in this statement are summarized in Table 2.
### KEY SUMMARY POINTS – TABLE 2

<table>
<thead>
<tr>
<th>Section</th>
<th>Notes</th>
</tr>
</thead>
</table>
| **Actions of cannabis in animal models** | • THC disrupts endocannabinoid signaling pathways and affects synaptic plasticity. In the short-term, this affects the strength of interneuronal connections; in the long-term, it leads to changes in the functioning of neuronal networks.  
• Exposure to THC during adolescence can lead to structural, molecular and functional alterations of brain circuits, particularly in areas involved in cognition and behavior |
| **Effect of Prenatal Exposure to Cannabinoid Agonists** | • In preclinical models, THC disrupts the normal signaling of the endocannabinoid system during development and throughout ontogenesis and results in abnormal neurotransmission.  
• Prenatal THC affects neuroanatomical areas associated with cognition and emotional regulation, including the pre-frontal cortex, limbic system, and ventral tegmentum of the midbrain |
| **Effects of marijuana use on human cognition** | • Acute consumption of marijuana affects memory, behavior and impulsivity.  
• The long-term effect of cannabis on cognition may be domain specific. Neuroimaging studies have shown structural changes in cannabis users; however, the results are inconsistent.  
• Functional changes may be observed in areas of the brain involved in cognition among cannabis users.  
• Early exposure to cannabis may have a negative effect on cognitive function. |
| **Effects of marijuana use on cerebrovascular risk and disease** | • Several studies have described an association between cannabis use and increased risk of stroke.  
• Data from population survey studies indicate the pattern (heavy vs. less) and frequency (>10 days/month) of cannabis use may increase the risk of stroke.  
• Cigarette smoking is common in cannabis users and may be an important modifier or confounder of the relationship between cannabis use and stroke risk.  
• Given the potential role of cannabis as a vasoactive substance, and its potential role in cardiac pathology as well as atherosclerosis development, cannabis use may also increase stroke risk via reversible cerebral vasoconstriction syndromes or may indirectly increase stroke risk.  
• It is possible that differences among some study findings may be attributable to the years in which population cohorts were studied or recruited, as most population cohorts were assembled prior to 2012. Over the last decade, strains of cannabis have been evolving resulting in plants with high THC concentrations and some preparations that may have synthetic cannabinoids, such as Spice, which may influence the association of cannabis use with stroke. |
| **Education and future directions** | • The cumulative evidence collected in clinical and preclinical studies suggests that the consumption of marijuana can have a detrimental effect on brain health. The exact ramifications, however, have not been precisely established.  
• Emerging evidence questions the widely accepted belief that marijuana is innocuous and suggests that cannabis, particularly THC, negatively affects brain health through direct and indirect mechanisms.  
• Health care professionals and consumers should receive education on the potential beneficial and harmful effects associated with the use of marijuana, including the increased risk of stroke and cognitive decline. |
EDUCATION AND FUTURE DIRECTIONS

• The overarching goal of this statement was to discuss mechanisms by which marijuana use could influence brain health.

• As the field is developing, several important aspects require additional research.

• There is limited information comparing the differential effect of recreational, illicit, or medicinal use of marijuana, as well as the type of cannabis product consumed.

• Similarly, the modulatory effects of social determinants of health and race/ethnicity on the interaction of brain health and marijuana use are largely unexplored.

• The latter area of research may be particularly important as communities of color in the United States may be disproportionately impacted by natural and synthetic cannabinoids in relation to use and exposure and the legal implications of criminalization of marijuana.

• Public health efforts should be considered to raise awareness about the potential negative effects associated with the use of marijuana in the general population.
EDUCATION AND FUTURE DIRECTIONS

• Possible strategies include using standardized concentrations of biologically active components and health warning labels on available formulations.
• The use of marijuana should be individualized and closely monitored.
• Healthcare providers and patients should receive unbiased education about the potential consequences of medicinal, recreational and illicit marijuana use on brain health, particularly when the exposure occurs during vulnerable vital periods.
• It may also be important for providers to monitor cognitive performance of marijuana users and review their medications to identify potential drug-to-drug interactions.
• Knowledgeable healthcare providers will be able to properly educate potential or active marijuana users about its possible adverse effects empowering them to make an informed decision based on unbiased data.